Quintiles Library

Precision Enrollment
Featured Video
Show Filters
White Paper
This white paper discusses partnering solutions that are specifically tailored for emerging biopharma. Given tremendous advances in this segment of the overall biopharmaceutical market, even though each company may only have one or two assets, the total pipeline is equivalent to roughly two-thirds of the entire global industry pipeline.Emerging biopharma is well served by...
Explore More
White Paper
Medical device makers are bullish about the future in general and about Asia-Pacific in particular. With a current commercial market size of USD $55 billion to $60 billion1,2, the region is a hot spot for medical device companies worldwide for sales, investment and expansion.This paper looks at the factors behind the attractiveness of Asia-Pacific for medical device...
Explore More
Fact Sheet
Today’s biosimilar landscape is characterized by rapid growth, intense competition, a diverse set of challenges, and large opportunities. As originator biologics go off patent, biotech companies are developing biosimilars to capture their share of a lucrative market. Sponsors aiming to capitalize on “first mover” advantages in major markets need an experienced partner...
Read More
Presentation
Learn more about Quintiles presentations and posters at ICPE 2016.
Explore More
Presentation
As an investigational compound progresses from early phase randomized clinical trials to being approved for prescribing to patients in physician practice, the research focus shifts from ‘Does the drug work’ to ‘Does the drug work in real world settings?’ Ideally, data collection on observational study designs should reflect standard of practice care at physician visits...
Explore More
White Paper
“The Art & Science of Evidence – Rare Disease: An integrated, patient-centered approach to research and commercialization” is one in a series of compendia featuring blogs and bylined articles from Quintiles’ experts. This collection highlights some of our recent thinking on how to better conduct rare disease research through patient-centric approaches to inform trial...
Explore More
Presentation
A comprehensive slide deck outlining Quintiles Pediatric Center of Excellence's core capabilities & differentiation.
Explore More
White Paper
Real-world evidence (RWE) studies – which are increasingly required to demonstrate product value in settings that reflect actual care settings – demand different approaches from traditional, randomized clinical trials. Data typically covers outcomes, and may come from observational studies, pragmatic trials, or database studies. This paper discusses best practices to...
Explore More
Article
These days, clinical trial sponsors are being asked to provide empirical evidence to many stakeholders with diverse needs and to do so efficiently. By taking a holistic view of post-approval evidence needs, it is possible to address many stakeholders' needs, thereby minimizing expense while increasing the likelihood of getting data that are fit for a variety of purposes.
Explore More
Article
Non-adherence is a shared issue, impacting all healthcare stakeholders. Patients will not gain the full benefit of their treatment, which may increase the need for medical intervention and even death. The healthcare system experiences inefficient use of resources and increased ong-term costs. The biopharma industry’s innovative products are not used effectively, leading...
Explore More
Article
When developing a new treatment for a rare disease, the first thing developers should do is build a patient registry for their target patient population. Rare disease patient registries are online platforms where patients and caregivers record information about their diagnosis, condition, and treatment experience. These platforms give developers a mechanism to gather...
Explore More
Fact Sheet
Implemented in July 2012, the new EU Pharmacovigilance regulations represent significant changes to human medicine regulation, shifting the focus of post-authorization safety from traditionally reactive risk management to the proactive analysis of product benefits as well as risks.
Read more
Press Release
RESEARCH TRIANGLE PARK, N.C. and MINNEAPOLIS – August 2, 2016 – Quintiles, the world’s largest provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a leader in kidney care, today announced a global strategic alliance. The alliance combines DaVita’s world-class...
Read More
Fact Sheet
Selecting the right development partner is a balancing act. Do you want a local partner or one with access to extensive global resources? Broad or focused expertise? High touch or high tech? Low cost or high value? With the Quintiles Asia Pacific Emerging Biopharma Solution, you no longer have to compromise. Working on more than 60 studies for more than 45 Asia Pacific...
Read More
Infographic
Working together, Quintiles and DaVita can combine world-class renal clinical care expertise with industry-leading clinical research acumen to help you meet your timelines.
Read More
Article
Over the past 30 years, our greatest accomplishments in advancing understanding about the safety, effectiveness and value of healthcare interventions have been achieved through the availability and accessibility of health insurance claims for large populations and, more recently, access to pockets of electronic health records that can be linked to information on...
Explore More
Press Release
8.6% service revenue growth, 7.9% at constant currency, compared to the second quarter of 2015 $0.93 diluted adjusted EPS representing 19.2% growth compared to the second quarter of 2015, with $0.71 diluted GAAP EPS representing 6.0% growth $1.64 billion of net new business in the second quarter of 2016 up 24.4% compared to the second quarter of 2015,...
Read More
Article
Healthcare systems and a variety of stakeholders are demanding convincing value data to show improved outcomes before approving new drugs. Quintiles' experts share their insight into combining strategic thinking with the ability to capture and analyze complex clinical data to effectively demonstrate real-world outcomes.  Learn why a clear understanding of stakeholder...
Explore More
Fact Sheet
Achieve better patient outcomes with fit-for-purpose study design and execution to meet the needs of regulators, payers, providers and patients. Quintiles’ dedicated real-world evidence team combines integrated partner services and operational expertise with innovative technology to guide you through the unique challenges of real-world evidence studies. Click on the...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – July 13, 2016 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its second quarter 2016 financial results Wednesday, July 27, 2016 prior to its quarterly earnings call at 8:00 a.m. EDT. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at...
Read More